Bei welchen Aktien geht nächte Woche die Post ab? o. T.
5 Postings ausgeblendet.
04.03.04 09:57
#9
petki
Postbank AG - der Zug ist abgefahren!
Die Deutsche Post hat das Gewinnziel für das vergangene Jahr von 2,9 Milliarden Euro habe die Post übertroffen. Bis 2005 wolle der Konzern das Ergebnis auf 3,6 Milliarden Euro steigern. Das Kostensenkungsprogramm Star habe 2003 höhere Verbesserungen als zunächst vorgesehen erzielt. Statt 350 Millionen Euro habe der Konzern Ergebnissteigerungen von 400 Millionen Euro erreicht.
04.03.04 10:05
#10
n1608
Hier geht die Post ab!
allerdings nicht nur diese Woche, sondern auch in den kommenden Monaten aber das sollte euch ja nicht stören.
Heiler Software WKN 542990
Hier informieren:
http://www.ariva.de/board/188350/...42990&search_id=&search_full=&591
&a=542990&b=0&banner_ref=HASH(0x996f2b0)&zeitraum=5&ind_volume=ON&zeitbis=&bname=&bis=1078391033&cookies=HASH(0x9bb8664)&req_host=www.ariva.de&zeitvon=&von=0&ind_gd38=ON "ariva.de")
Syzygy WKN 510480
&a=510480&b=0&banner_ref=HASH(0xa015300)&zeitraum=5&ind_volume=ON&zeitbis=&bname=&bis=1078391088.77705&cookies=HASH(0x9f7ecf4)&req_host=www.ariva.de&zeitvon=&von=0&ind_gd38=ON "ariva.de")
Heiler Software WKN 542990
Hier informieren:
http://www.ariva.de/board/188350/...42990&search_id=&search_full=&591
Syzygy WKN 510480
07.03.04 19:45
#15
lancerevo7
meine favoriten
meine favoriten für die nächsten wochen und monate:
SOFTSHIP AG HAMBURG (WKN 575830): Bringen SuperSuperSuper-Zahlen für 2003 Ende März raus. Der Kurs hat am Freitag +10% gemacht, dies alleine wegen dem Zuzug eines neuen Kunden. Wie reagiert der Kurs wohl bei der Präsentation der Zahlen ?
INNOVATION HOLDINGS INC.: Kurz vor Übernahme der hocchprofitablen BikiniVending ? Kurs noch bei 0,0002 - Falls Übernahme endlich zustande kommen würde wären bis Ende 2004 Kurse um +5000% möglich. Jahr 2002: Verlust 41 Mio. US-$ / Jahr 2003: Verlust 7 Mio. US-$ (estimated) und Jahr 2004: Verlust 2-3 Mio. US-$ (est.) und 2005 Gewinnzone ?
Wenn der Akt mit BVending klappt könnten aus 1000Euro 50000Euro locker werden.
greez lancer7
SOFTSHIP AG HAMBURG (WKN 575830): Bringen SuperSuperSuper-Zahlen für 2003 Ende März raus. Der Kurs hat am Freitag +10% gemacht, dies alleine wegen dem Zuzug eines neuen Kunden. Wie reagiert der Kurs wohl bei der Präsentation der Zahlen ?
INNOVATION HOLDINGS INC.: Kurz vor Übernahme der hocchprofitablen BikiniVending ? Kurs noch bei 0,0002 - Falls Übernahme endlich zustande kommen würde wären bis Ende 2004 Kurse um +5000% möglich. Jahr 2002: Verlust 41 Mio. US-$ / Jahr 2003: Verlust 7 Mio. US-$ (estimated) und Jahr 2004: Verlust 2-3 Mio. US-$ (est.) und 2005 Gewinnzone ?
Wenn der Akt mit BVending klappt könnten aus 1000Euro 50000Euro locker werden.
greez lancer7
07.03.04 20:41
#20
soros
Siehe letzten 2 News!
Mein Tip:WKN:894679 (Bio)
Last Sale: 0.16 +0.05 +45.45% Company Profile
Volume: 78,040 Previous Close: 0.11 (3/5/2004)
03:58:04 PM 3/05/2004
Today's High: 0.16
Today's Low: 0.14
Best Bid: 0.16 Best Ask: 0.2
Share Data
Market News
--------------------------------------------------
BLFS BIOLIFE SOLUTIONS INC
ENDO ENDOCARE INC
--------------------------------------------------
BioLife Solutions Settles Dispute With Endocare
THURSDAY , MARCH 04, 2004 01:30 AM
BINGHAMTON, N.Y., Mar 4, 2004 /PRNewswire-FirstCall via COMTEX/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS) announced today the settlement of a dispute between the Company and Irvine, CA-based Endocare, Inc. (OTC: ENDO), arising out of Endocare's failure to register stock delivered to BioLife as part of the transaction by which BioLife sold its cryosurgical equipment assets to Endocare on June 24, 2002. Under the settlement, Endocare will make a one- time payment to BioLife of $1.87 million.
BioLife President and CEO John G. Baust, Ph.D., said, "It is with great pleasure that we have settled our dispute with Endocare. This will allow the Company to pay outstanding loans, reduce its payables, and move forward with its business strategy. We continue to strive to expand our customer base and to position BioLife to derive growing revenue streams from a broader base of customers."
About BioLife Solutions, Inc.
BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented under-standing of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol(R) and CryoStor(TM) products that the Company is selling today are a significant step forward in meeting these needs.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
For further information, please contact: investors, Jill Bertotti , jill@allencaron.com or media, Len Hall, len@allencaron.com , both of Allen & Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.
SOURCE BioLife Solutions Inc.
Last Sale: 0.16 +0.05 +45.45% Company Profile
Volume: 78,040 Previous Close: 0.11 (3/5/2004)
03:58:04 PM 3/05/2004
Today's High: 0.16
Today's Low: 0.14
Best Bid: 0.16 Best Ask: 0.2
Share Data
Market News
--------------------------------------------------
BLFS BIOLIFE SOLUTIONS INC
ENDO ENDOCARE INC
--------------------------------------------------
BioLife Solutions Settles Dispute With Endocare
THURSDAY , MARCH 04, 2004 01:30 AM
BINGHAMTON, N.Y., Mar 4, 2004 /PRNewswire-FirstCall via COMTEX/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS) announced today the settlement of a dispute between the Company and Irvine, CA-based Endocare, Inc. (OTC: ENDO), arising out of Endocare's failure to register stock delivered to BioLife as part of the transaction by which BioLife sold its cryosurgical equipment assets to Endocare on June 24, 2002. Under the settlement, Endocare will make a one- time payment to BioLife of $1.87 million.
BioLife President and CEO John G. Baust, Ph.D., said, "It is with great pleasure that we have settled our dispute with Endocare. This will allow the Company to pay outstanding loans, reduce its payables, and move forward with its business strategy. We continue to strive to expand our customer base and to position BioLife to derive growing revenue streams from a broader base of customers."
About BioLife Solutions, Inc.
BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented under-standing of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol(R) and CryoStor(TM) products that the Company is selling today are a significant step forward in meeting these needs.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
For further information, please contact: investors, Jill Bertotti , jill@allencaron.com or media, Len Hall, len@allencaron.com , both of Allen & Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.
SOURCE BioLife Solutions Inc.